Citadel Advisors’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13.9M | Sell |
428,300
-507,300
| -54% | -$16.3M | ﹤0.01% | 2776 |
|
|
2025
Q4 | $32.9M | Sell |
935,600
-297,000
| -24% | -$10.5M | ﹤0.01% | 1823 |
|
|
2025
Q3 | $32.4M | Buy |
1,232,600
+442,000
| +56% | +$13.2M | ﹤0.01% | 1796 |
|
|
2025
Q2 | $21M | Sell |
790,600
-51,900
| -6% | -$1.37M | ﹤0.01% | 2083 |
|
|
2025
Q1 | $20.3M | Sell |
842,500
-444,000
| -35% | -$14M | ﹤0.01% | 2019 |
|
|
2024
Q4 | $51.8M | Sell |
1,286,500
-6,600
| -0.5% | -$376K | 0.01% | 1240 |
|
|
2024
Q3 | $81.9M | Buy |
1,293,100
+640,100
| +98% | +$37.6M | 0.02% | 835 |
|
|
2024
Q2 | $34.6M | Sell |
653,000
-264,500
| -29% | -$17.3M | 0.01% | 1475 |
|
|
2024
Q1 | $75.2M | Buy |
917,500
+684,400
| +294% | +$30.5M | 0.01% | 911 |
|
|
2023
Q4 | $4.34M | Buy |
233,100
+31,500
| +16% | +$412K | ﹤0.01% | 4013 |
|
|
2023
Q3 | $2.23M | Sell |
201,600
-146,500
| -42% | -$2.1M | ﹤0.01% | 5032 |
|
|
2023
Q2 | $5.64M | Buy |
348,100
+45,400
| +15% | +$951K | ﹤0.01% | 3461 |
|
|
2023
Q1 | $5.04M | Buy |
302,700
+144,500
| +91% | +$1.49M | ﹤0.01% | 3807 |
|
|
2022
Q4 | $1.49M | Buy |
158,200
+113,100
| +251% | +$505K | ﹤0.01% | 6050 |
|
|
2022
Q3 | $123K | Buy |
45,100
+100
| +0.2% | +$328 | ﹤0.01% | 10913 |
|
|
2022
Q2 | $130K | Sell |
45,000
-16,800
| -27% | -$41.6K | ﹤0.01% | 11135 |
|
|
2022
Q1 | $185K | Sell |
61,800
-17,700
| -22% | -$63.5K | ﹤0.01% | 11632 |
|
|
2021
Q4 | $366K | Sell |
79,500
-19,700
| -20% | -$110K | ﹤0.01% | 10466 |
|
|
2021
Q3 | $623K | Sell |
99,200
-8,600
| -8% | -$53.1K | ﹤0.01% | 9338 |
|
|
2021
Q2 | $646K | Buy |
107,800
+15,300
| +17% | +$90.8K | ﹤0.01% | 9434 |
|
|
2021
Q1 | $585K | Buy |
92,500
+1,500
| +2% | +$10.6K | ﹤0.01% | 9340 |
|
|
2020
Q4 | $512K | Sell |
91,000
-16,300
| -15% | -$98.7K | ﹤0.01% | 8098 |
|
|
2020
Q3 | $624K | Buy |
107,300
+11,100
| +12% | +$76.4K | ﹤0.01% | 6888 |
|
|
2020
Q2 | $694K | Buy |
96,200
+1,900
| +2% | +$12.6K | ﹤0.01% | 6493 |
|
|
2020
Q1 | $441K | Sell |
94,300
-99,600
| -51% | -$612K | ﹤0.01% | 6676 |
|
|
2019
Q4 | $1.55M | Buy |
193,900
+70,800
| +58% | +$516K | ﹤0.01% | 4823 |
|
|
2019
Q3 | $847K | Sell |
123,100
-32,400
| -21% | -$241K | ﹤0.01% | 5877 |
|
|
2019
Q2 | $1.29M | Sell |
155,500
-35,700
| -19% | -$305K | ﹤0.01% | 5288 |
|
|
2019
Q1 | $1.9M | Buy |
191,200
+27,500
| +17% | +$230K | ﹤0.01% | 4546 |
|
|
2018
Q4 | $1.25M | Sell |
163,700
-64,000
| -28% | -$765K | ﹤0.01% | 4954 |
|
|
2018
Q3 | $3.97M | Sell |
227,700
-31,000
| -12% | -$369K | ﹤0.01% | 3310 |
|
|
2018
Q2 | $2.46M | Buy |
+258,700
| New | +$1.72M | ﹤0.01% | 3787 |
|
Other funds holding VKTX
VCM
VPM
Citadel Advisors's VKTX Position: Q1 2026 in Review
Citadel Advisors reduced its Viking Therapeutics (VKTX) stake by 27% in Q1 2026, selling an estimated $15.1M and leaving 1,262,221 shares worth $41.1M. The position accounts for 0.01% of the portfolio, ranked #1545.
Citadel Advisors first reported a position in VKTX in Q1 2016 and has held it in 33 quarters since. The position peaked at $93.2M in Q3 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.
- Citadel Advisors held 1,262,221 shares of Viking Therapeutics worth $41.1M as of Q1 2026.
- Citadel Advisors sold 470,200 Viking Therapeutics shares in Q1 2026, an estimated $15.1M.
- Viking Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1545 holding.
- Citadel Advisors first reported a position in Viking Therapeutics in Q1 2016 and has held it in 33 quarters since.
- Citadel Advisors's Viking Therapeutics position peaked at $93.2M in Q3 2024.
- 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.